ADVA
20.12.2019 09:02:09 CET | Business Wire | Press release
ADVA (FSE: ADV) today announced that its FSP 150-XG480 has become the first 100Gbit/s solution on the market to achieve MEF 3.0 Carrier Ethernet certification. The compact metro edge device is now the industry’s only 100Gbit/s packet aggregation and demarcation technology proven to offer the highest available levels of performance, assurance and agility. With the ADVA FSP 150-XG480, enterprises and communication service providers (CSPs) can address the boom in cloud computing and mobile services by smoothly transitioning to 10 and 25Gbit/s service aggregation. What’s more, ADVA’s MEF 3.0-compliant technology enables them to meet the need for high-capacity wholesale, mobile and business services with a solution that supports automated networking and 5G-ready architectures.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191220005017/en/
“CSPs now have the power to tackle the demand for 100Gbit/s aggregation at the metro edge with a solution guaranteed to deliver the highest industry standards for performance and assurance. With our unique technology, there’s now a simple and extremely cost-efficient route to MEF 3.0-certified 100Gbit/s service aggregation,” said James Buchanan, GM, Edge Cloud, ADVA. “Higher speeds in the access network are becoming essential. In fact, with the emergence of more and more connected devices as well as the unprecedented surge in video streaming platforms, 10Gbit/s is becoming the new 1Gbit/s. What our FSP 150-XG480 offers is a future-proof way to deliver MEF CE services up to 100Gbit/s and enable the efficient and reliable aggregation of multiple 10Gbit/s streams.”
The compact and powerful ADVA FSP 150-XG480 aggregator with high-density 1, 10 and 25Gbit/s port count is the ultimate tool for fighting bandwidth bottlenecks and evolving metro networks to 100Gbit/s. Its MEF 3.0-compliant interfaces and operation and management capabilities enable seamless integration into existing networks and established processes. The ADVA FSP 150-XG480 offers a range of advantages for connectivity and synchronization in mobile backhaul networks. These include leveraging ADVA’s Oscilloquartz Syncjack™ technology to constantly control the accuracy of network timing. It’s also the only device available with 100Gbit/s line-rate service activation and testing, so there’s no need for CSPs to compromise on high-value SLA-based business services.
“Achieving MEF 3.0-compliant status with our FSP 150-XG480 highlights the leading role ADVA continues to play in the Carrier Ethernet space. This certification is also great news for enterprises across the world as well as mobile network operators looking to meet soaring data demand. Now they can map 10 and 25GbE into 100Gbit/s aggregated bandwidth with a solution that easily expands to meet the coming requirements of 5G networks,” commented Eli Angel, VP, product line management, Ethernet access, ADVA. “Our FSP 150-XG480 is the key to future scalability. It also features an incredibly small form factor and environmentally hardened design, delivering a significant cost advantage over competing technology.”
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we're building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20191220005017/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom